Global Bio Fund, alongside Even Capital and other investors, has invested A$4.565 million in the Australian women-led med-tech company Baymatob to support the development of its innovative postpartum hemorrhage detection device, Oli.

Target Information

Baymatob is an innovative Australian med-tech company founded by Dr. Sarah McDonald, an engineer and mother, in response to her own challenging birthing experience. The firm specializes in developing a wearable medical device named Oli, which leverages artificial intelligence to identify pregnant women who are at a high risk of postpartum hemorrhage (PPH) during labor. This critical condition is recognized as the leading cause of preventable maternal deaths globally, with one mother succumbing to PPH every seven minutes. The company's mission is to enhance maternal safety and improve outcomes surrounding childbirth.

Baymatob's device, Oli, has gained significant recognition in the medical community. In August 2021, it received the Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which allows for an expedited regulatory review process. This status confirms the potential of Oli to significantly impact clinical practices in the U.S., and it positions the company favorably for timely access to crucial clinical pathways.

Industry Overview

The med-tech industry in Australia has been experiencing robust growth, driven by increased health expenditures and a focus on innovative healthcare solutions. With a strong emphasis on research and development, Australia has esta